Denali Advisors LLC Reduces Stock Holdings in McKesson Corporation $MCK

Denali Advisors LLC reduced its position in shares of McKesson Corporation (NYSE:MCK) by 41.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,725 shares of the company’s stock after selling 1,229 shares during the quarter. Denali Advisors LLC’s holdings in McKesson were worth $1,333,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MCK. Solstein Capital LLC boosted its holdings in shares of McKesson by 171.4% in the second quarter. Solstein Capital LLC now owns 38 shares of the company’s stock worth $28,000 after buying an additional 24 shares during the last quarter. State of Wyoming bought a new position in McKesson in the second quarter worth approximately $29,000. Hopwood Financial Services Inc. purchased a new position in shares of McKesson during the 3rd quarter worth $31,000. Delos Wealth Advisors LLC bought a new stake in shares of McKesson during the 2nd quarter valued at $35,000. Finally, Abound Wealth Management increased its stake in shares of McKesson by 104.3% in the 3rd quarter. Abound Wealth Management now owns 47 shares of the company’s stock worth $37,000 after purchasing an additional 24 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Trading Up 1.9%

NYSE MCK opened at $933.75 on Tuesday. McKesson Corporation has a 12 month low of $585.22 and a 12 month high of $971.93. The stock has a market cap of $114.38 billion, a PE ratio of 26.86, a P/E/G ratio of 1.50 and a beta of 0.40. The stock’s 50 day moving average is $842.86 and its 200 day moving average is $790.27.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter last year, the business posted $8.03 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts forecast that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. This represents a 10.85% decrease in their position. The SEC filing for this sale provides additional information. 0.08% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MCK. Weiss Ratings downgraded McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Mizuho lifted their price objective on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price objective on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Wells Fargo & Company raised their target price on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Finally, TD Cowen upped their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $937.07.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.